Literature DB >> 33055248

In Vitro Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with In Vivo Susceptibility.

Ju Hwan Jeong1, Won-Suk Choi1, Khristine Joy C Antigua1, Young Ki Choi1, Elena A Govorkova2, Richard J Webby2, Yun Hee Baek3, Min-Suk Song3.   

Abstract

Laninamivir (LAN) is a long-acting neuraminidase (NA) inhibitor (NAI) with a similar binding profile in the influenza NA enzyme active site as those of other NAIs, oseltamivir (OS), zanamivir (ZAN), and peramivir, and may share common resistance markers with these NAIs. We screened viruses with NA substitutions previously found during OS and ZAN selection in avian influenza viruses (AIVs) of the N3 to N9 subtypes for LAN susceptibility. Of the 72 NA substitutions, 19 conferred resistance to LAN, which ranged from 11.2- to 549.8-fold-decreased inhibitory activity over that of their parental viruses. Ten NA substitutions reduced the susceptibility to all four NAIs, whereas the remaining 26 substitutions yielded susceptibility to one or more NAIs. To determine whether the in vitro susceptibility of multi-NAI-resistant AIVs is associated with in vivo susceptibility, we infected BALB/c mice with recombinant AIVs with R292K (ma81K-N3R292K) or Q136K (ma81K-N8Q136K) NA substitutions, which impart in vitro susceptibility only to LAN or OS, respectively. Both ma81K-N3R292K and ma81K-N8Q136K virus-infected mice exhibited reduced weight loss, mortality, and lung viral titers when treated with their susceptible NAIs, confirming the in vitro susceptibility of these substitutions. Together, LAN resistance profiling of AIVs of a range of NA subtypes improves the understanding of NAI resistance mechanisms. Furthermore, the association of in vitro and in vivo NAI susceptibility indicates that our models are useful tools for monitoring NAI susceptibility of AIVs.IMPORTANCE The chemical structures of neuraminidase inhibitors (NAIs) possess similarities, but slight differences can result in variable susceptibility of avian influenza viruses (AIVs) carrying resistance-associated NA substitutions. Therefore, comprehensive susceptibility profiling of these substitutions in AIVs is critical for understanding the mechanism of antiviral resistance. In this study, we profiled resistance to the anti-influenza drug laninamivir in AIVs with substitutions known to impart resistance to other NAIs. We found 10 substitutions that conferred resistance to all four NAIs tested. On the other hand, we found that the remaining 26 NA substitutions were susceptible to at least one or more NAIs and showed for a small selection that in vitro data predicted in vivo behavior. Therefore, our findings highlight the usefulness of screening resistance markers in NA enzyme inhibition assays and animal models of AIV infections.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  avian influenza virus; in vivo efficacy; laninamivir; mouse model; neuraminidase inhibitor; profiling; resistance

Mesh:

Substances:

Year:  2020        PMID: 33055248      PMCID: PMC7737746          DOI: 10.1128/JVI.01679-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.

Authors:  Hui-Ling Yen; Erich Hoffmann; Garry Taylor; Christoph Scholtissek; Arnold S Monto; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  A DNA transfection system for generation of influenza A virus from eight plasmids.

Authors:  E Hoffmann; G Neumann; Y Kawaoka; G Hobom; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 3.  Treatment of influenza with neuraminidase inhibitors.

Authors:  Kate R Beard; Nathan J Brendish; Tristan W Clark
Journal:  Curr Opin Infect Dis       Date:  2018-12       Impact factor: 4.915

4.  E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.

Authors:  Arnaud G L'Huillier; Yacine Abed; Tom J Petty; Samuel Cordey; Yves Thomas; Xavier Bouhy; Manuel Schibler; Audrey Simon; Yves Chalandon; Christian van Delden; Evgeny Zdobnov; Patricia Boquete-Suter; Guy Boivin; Laurent Kaiser
Journal:  J Infect Dis       Date:  2015-05-17       Impact factor: 5.226

5.  Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic.

Authors:  David A Boltz; Bounlom Douangngeun; Phouvong Phommachanh; Settha Sinthasak; Ricarda Mondry; Caroline Obert; Patrick Seiler; Rachael Keating; Yasuo Suzuki; Hiroaki Hiramatsu; Elena A Govorkova; Robert G Webster
Journal:  J Gen Virol       Date:  2009-12-16       Impact factor: 3.891

6.  Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013.

Authors:  T Kageyama; S Fujisaki; E Takashita; H Xu; S Yamada; Y Uchida; G Neumann; T Saito; Y Kawaoka; M Tashiro
Journal:  Euro Surveill       Date:  2013-04-11

7.  Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice.

Authors:  L V Gubareva; J A McCullers; R C Bethell; R G Webster
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

8.  Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.

Authors:  Elena A Govorkova; Natalia A Ilyushina; David A Boltz; Alan Douglas; Neziha Yilmaz; Robert G Webster
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

9.  Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.

Authors:  Christopher J Vavricka; Qing Li; Yan Wu; Jianxun Qi; Mingyang Wang; Yue Liu; Feng Gao; Jun Liu; Enguang Feng; Jianhua He; Jinfang Wang; Hong Liu; Hualiang Jiang; George F Gao
Journal:  PLoS Pathog       Date:  2011-10-20       Impact factor: 6.823

10.  Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.

Authors:  Shinya Omoto; Valentina Speranzini; Takashi Hashimoto; Takeshi Noshi; Hiroto Yamaguchi; Makoto Kawai; Keiko Kawaguchi; Takeki Uehara; Takao Shishido; Akira Naito; Stephen Cusack
Journal:  Sci Rep       Date:  2018-06-25       Impact factor: 4.379

View more
  1 in total

Review 1.  Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.

Authors:  Yaqin Bai; Jeremy C Jones; Sook-San Wong; Mark Zanin
Journal:  Viruses       Date:  2021-04-06       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.